You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 246 No. 1, July 3, 1981 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (25)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Role of Radioimmunodetection in the Management of Testicular Cancer

Nasser Javadpour, MD; E. Edmund Kim, MD; Frank H. DeLand, MD; Jimmy R. Salyer; Usha Shah; David M. Goldenberg, ScD, MD

JAMA. 1981;246(1):45-49.


Abstract

Five patients with testicular cancer received an intravenous injection of between 1 and 2.5 mCi of iodine 131—labeled antibody to human chorionic gonadotropin (HCG) or {alpha}-fetoprotein (AFP), followed by total-body photoscanning to visualize areas of abnormal radioactivity. Blood-pool and nontarget sites of radioactivity were reduced by subtracting the images derived by injection of technetium Tc 99m—labeled components from the iodine 131 scans. The HCG-immune scintiscans proved helpful in tumor localization and in the selection of appropriate therapy, while the AFP scan presented corroborative evidence of widespread tumor. Elevated serum levels of these two markers did not hinder successful tumor detection and localization by this method of radioimmunodetection. Cancer radioimmunodetection with antibodies to HCG and to AFP appears to be a useful procedure for the pretreatment and posttreatment evaluation of patients with testicular cancer and can reveal sites of tumor not detected by other methods.

(JAMA 1981;246:45-49)



Author Affiliations

From the Surgery Branch (Dr Javadpour) and the Immunology Branch (Dr Goldenberg), the National Cancer Institute, National Institutes of Health, Bethesda, Md; and the Departments of Radiation Medicine (Drs Kim and DeLand) and Pathology (Mr Salyer, Ms Shah, and Dr Goldenberg), University of Kentucky and Veterans Administration Medical Centers, Lexington.


Footnotes

Reprint requests to Division of Experimental Pathology, MS-409, University of Kentucky College of Medicine, Lexington, KY 40536 (Dr Goldenberg).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Radioimmunodetection of Prostatic Cancer: In Vivo Use of Radioactive Antibodies Against Prostatic Acid Phosphatase for Diagnosis and Detection of Prostatic Cancer by Nuclear Imaging
Goldenberg et al.
JAMA 1983;250:630-635.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1981 American Medical Association. All Rights Reserved.